TABLE 2

Proportion of participants with adverse respiratory events

MRI-guided BTStandard BT
Intervention period plus 6 weeks
 SAE – hospitalisation2/5 (40%)1/7 (14%)
 Cough4/5 (80%)6/7 (86%)
 Wheeze3/5 (60%)4/7 (57%)
 Chest tightness1/5 (20%)4/7 (57%)
 Consolidation/atelectasis/airspace opacity2/5 (40%)4/7 (57%)
 Dyspnoea2/5 (40%)3/7 (43%)
 Chest discomfort1/5 (20%)3/7 (43%)
 Bronchospasm1/5 (20%)3/7 (43%)
 Haemoptysis0/5 (0%)3/7 (43%)
 Productive cough1/5 (20%)3/7 (43%)
 Decreased breath sounds2/5 (40%)2/7 (29%)
 Sputum discoloured2/5 (40%)0/7 (0%)
 Infection2/5 (40%)1/7 (14%)
 Fever1/5 (20%)1/7 (14%)
 Night awakenings0/5 (0%)1/7 (14%)
 Bronchospasm0/5 (0%)1/7 (14%)
Post-intervention period (6 weeks–12 months)
 SAE – hospitalisation1/5 (20%)2/7 (29%)
 Cough2/5 (40%)4/7 (57%)
 Dyspnoea3/5 (60%)4/7 (57%)
 Chest tightness1/5 (20%)4/7 (57%)
 Wheeze2/5 (40%)3/7 (43%)
 Productive cough1/5 (20%)3/7 (43%)
 Infection1/5 (20%)3/7 (43%)
 Chest discomfort0/5 (0%)2/7 (29%)
 Night awakenings0/5 (0%)2/7 (29%)
 Sputum discoloured1/5 (20%)1/7 (14%)
 Decreased breath sounds1/5 (20%)1/7 (14%)
 Fever0/5 (0%)1/7 (14%)

Data are presented as n/N (%). MRI: magnetic resonance imaging; BT: bronchial thermoplasty; SAE: severe adverse event.